Wide-neck intracranial aneurysms had previously been difficult to treat with primary coiling given the risk of coil herniation into the parent artery and subsequent thromboembolic events. These aneurysms would then be treated with microsurgical clipping or endovascular coiling with adjuncts such as balloon-and stent-assistance or flow-diverting stents. The Woven EndoBridge (WEB) device (Terumo Neuro, Alisa Viejo, CA) is an intrasaccular device used to treat wide-neck intracranial aneurysms. The WEB device uses a braided-mesh forming a hollow ball of nitinol wires with a platinum core and is MRI compatible. The second iteration of the WEB device was shown to be safe in the prospective multi-center WEB Intra-saccular Therapy (WEB-IT) study with no rebleeding and minimal morbidity at 5 year follow-up. ^{Reference Fiorella, Molyneux and Coon1}

One of the benefits of this endovascular approach is that there is minimal metallic material within the parent artery, therefore making postoperative antiplatelet therapy potentially optional. A limitation of WEB device treatment is that the aneurysm does not fully occlude immediately, which would be more concerning in the setting of a ruptured aneurysm. Antiplatelet use such as aspirin (ASA) after WEB device placement is left at the discretion of the treating team, balancing the prevention of thromboembolic events with aneurysm rebleeding.

Musmar and colleagues show in their multi-center, retrospective, propensity score-matching study of both ruptured and unruptured brain aneurysms treated with WEB device that postoperative ASA use is safe. ^{Reference Musmar, Salim and Roy2} Moreover, the authors found that postoperative ASA was associated with lower retreatment rates compared with no antiplatelet treatment, although the mechanism for enhancing aneurysm stability remains unclear. A limitation of this study is the fact that patients treated with dual antiplatelets were excluded from the analysis. This study gives more confidence to neurointerventionalists who already administer ASA post WEB treatment. This study allows those who do not currently use antiplatelets post WEB treatment to at least think about this option.